CNBX Pharmaceuticals Inc. (CNBX)
OID · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About CNBX Pharmaceuticals Inc.
CNBX Pharmaceuticals Inc., a clinical-stage company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. Its lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome. The company is also developing various drug candidates, including PLP-33 for the local treatment of lateral spreading, or sessile, colorectal polyps during colonoscopy, BRST-33 for the treatment of breast cancer, MLN-33 for the treatment of melanoma, and PRST-33 for the treatment of prostate cancer. In addition, it is developing RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer. The company was formerly known as Cannabics Pharmaceuticals Inc. and changed its name to CNBX Pharmaceuticals Inc. in March 2022. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland.
Quarterly Financials
| Metric | 2025-05-31 | 2025-08-31 | 2025-11-30 | 2026-02-28 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | |||
| Operating Income | -40K | -130K | -64K | -73K |
| Net Income | -60K | -150K | -114K | -44K |
| Diluted EPS | $0.00 | $nan | $0.00 | $0.00 |
Annual Financials
| Metric | 2022-08-31 | 2023-08-31 | 2024-08-31 | 2025-08-31 |
|---|---|---|---|---|
| Revenue | 30K | 410K | 130K | 0.00 |
| Operating Income | -3.0M | -931K | -583K | -272K |
| Net Income | -4.4M | -3.7M | -695K | -314K |
| Diluted EPS | $-3.59 | $-0.42 | $-0.02 | $0.00 |